EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The adverse prognosis of most patients with ovarian cancer is related to recurrent disease caused by resistance to chemotherapeutic and targeted therapeutics. Besides their direct activity against tumor cells, monoclonal antibodies and tyrosine kinase inhibitors (TKIs) also influence the antitumoral activity of immune cells, which has important implications for the design of immunotherapies. In this preclinical study, we treated different ovarian cancer cell lines with anti-epidermal growth factor receptor (EGFR) TKIs and co-incubated them with natural killer (NK) cells. We studied treatment-related structural and functional changes on tumor and immune cells in the presence of the anti-EGFR antibody cetuximab and investigated NK-mediated antitumoral activity. We show that long-term exposure of ovarian cancer cells to TKIs leads to reduced responsiveness of intrinsically sensitive cancer cells over time. Inversely, neither long-term treatment with TKIs nor cetuximab could overcome the intrinsic resistance of certain ovarian cancer cells to anti-EGFR agents. Remarkably, tumor cells pretreated with anti-EGFR TKIs showed increased sensitivity towards NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). In contrast, the cytokine secretion of NK cells was reduced by TKI sensitization. Our data suggest that sensitization of tumor cells by anti-EGFR TKIs differentially modulates interactions with NK cells. These data have important implications for the design of chemo-immuno combination therapies in this tumor entity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“induction of NK-cell-mediated ADCC of ovarian cancer and NSCLC cells”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Mallmann-Gottschalk et al., 2019
Experimental — accuracy not yet measuredIn the citing paper
“Not only EGFR-specific mAbs (Roberti et al., 2011) but also EGFR-targeting TKIs such as erlotinib (in the presence of a tumor-targeting mAb) (Cavazzoni et al., 2012; Mallmann-Gottschalk et al., 2019) promote ADCC by NK cells, which, in the case of TKIs, originates from the upregulation of the mAb target (e.g., EGFR, HER2) by malignant cells (Cavazzoni et al., 2012; Mallmann-Gottschalk et al., 2019”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Mallmann-Gottschalk et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104 · cited 1×
“The MTT colorimetric assay was performed to assess tumor cell viability under anti-EGFR-targeted therapy [49].”
MethodLynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726 · cited 1×
“approved for the treatment of metastatic colorectal cancer and advanced head and neck cancer [7,8].”
BackgroundK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · cited 1×
“K-ras mutations and changed EGFR degradation and internalization may provoke resistance to anti-EGFR antibodies [19,20].”
BackgroundA Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172 · cited 1×
“Radical resection followed by platinum-taxane-based chemotherapy recently combined with the anti-VEGF-inhibitor bevacizumab has improved prognosis in the last decade [2].”
BackgroundSelf-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904 · cited 1×
“approved for the treatment of metastatic colorectal cancer and advanced head and neck cancer [7,8].”
BackgroundCetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
CD107a as a functional marker for the identification of natural killer cell activity
Alter, G., Malenfant, J. M., & Altfeld, M. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.08.008 · Cited by 1,410 · cited 1×
“Since the lysosomal-associated membrane protein-1 (LAMP-1 or CD107a) in NK cells is expressed during degranulation and correlates with NK cell-mediated tumor cell lysis [50], the expression of CD107a on NK cells was used to evaluate natural and antibody-mediated NK cell cytotoxicity.”
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255 · cited 1×
“In in vitro and in vivo studies, the chimeric monoclonal antibody cetuximab displays antiproliferative and apoptotic effects and is able to reduce chemotherapy resistance in various human cancer entities including ovarian cancer [5,6].”
BackgroundDendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 887
Cited by
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Baci, D., Bosi, A., Gallazzi, M., Rizzi, M., Noonan, D. M., Poggi, A. D., Bruno, A., & Mortara, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093125 · Cited by 144
“Abbreviations HB-EGF Heparin-Binding EGF-like Growth Factor HGSOC High-Grade Serous Ovarian Cancer HSCs Hematopoietic Stem Cells Hu-mAb Humanized monoclonal antibodies IFNγ Interferon γ iNOS Inducible Nitric Oxide Synthase iPSC Induced Pluripotent Stem Cell LPS Lipo Poly Saccharide MCP-1/CCL2 Monocyte Chemoattractant…”
BackgroundInfluentialAn immunogenomic signature for molecular classification in hepatocellular carcinoma
Zhuang, W., Sun, H., Zhang, S., Zhou, Y., Weng, W., Wu, B., Ye, T., Huang, W., Lin, Z., Shi, L., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.024 · Cited by 71
“NK cells have strong anti-tumor activity and release perforin/granzymes or activate apoptosis pathways to kill tumor cells.(9) In addition, NK cells can also secrete cytokines, such as interferon (IFN)-g and tumor necrosis factor (TNF)-a, to inhibit tumor cell proliferation, tumor angiogenesis, and multistage cancerat…”
BackgroundBaysal, H., Pauw, I. D., Zaryouh, H., Peeters, M., Vermorken, J. B., Lardon, F., Waele, J. D., & Wouters, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737311 · Cited by 65
Metadata
- Authors
- Mallmann-Gottschalk, N., Sax, Y., Kimmig, R., Lang, S., & Brandau, S.
- Affiliations
- Department of Gynecology and Obstetrics, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany
- University of Duisburg-Essen (DE)
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-09-22
- Volume
- 20
- Issue
- 19
- Pages
- 4693
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6801374
- OpenAlex
- W2973955555
- Cited by
- 31
- References
- 50
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 4 · 2021: 8 · 2020: 7
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deutsche Forschungsgemeinschaft
- Universität Duisburg-Essen
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- ovarian cancer, EGFR tyrosine kinase inhibitors, cetuximab, natural killer cells, NK cell cytotoxicity, antibody-dependent cellular cytotoxicity, anti-EGFR antibody resistance, tumor sensitization, immunotherapy
- MeSH terms
- Antineoplastic Agents, Immunological, Antibody-Dependent Cell Cytotoxicity, Cell Survival, Cytotoxicity, Immunologic, Female, Humans, Killer Cells, Natural, Ligands, Ovarian Neoplasms, Biomarkers, Cytokines, Cell Line, Tumor, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells. https://app.cochat.ai/papers/10.3390/ijms20194693
- The paper
- Mallmann-Gottschalk, N., Sax, Y., Kimmig, R., Lang, S., & Brandau, S. (2019). EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms20194693
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.